At a glance
- Originator Shionogi
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Oct 1999 Preclinical development for Cancer in Japan (Unknown route)